ATYR — aTYR PHARMA INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1339970 ·
Last close
$4.99
Market Cap
$12.47M
52W High
$44.40
52W Low
$4.08
ADV30
91,280
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -18,792,000 | -18,261,000 | 59,806,000 | 13,140,000 | 26,014,000 |
| Jun 2026 | 0 | — | -10,881,000 | -10,309,000 | 69,825,000 | 16,160,000 | 21,231,000 |
| Mar 2026 | 0 | — | -11,436,000 | -10,791,000 | 79,654,000 | 10,008,000 | 21,913,000 |
| Dec 2025 | 0 | — | -14,796,000 | -13,963,000 | 93,003,000 | 10,743,000 | 25,715,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-54,540,000
Investing CF
$22,882,000
Financing CF
$29,215,000
CapEx
$-279,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-24.80
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-627,264,000
Inventory
—
Receivables
$426,000
ST Investments
$41,258,000
EBIT TTM
$-63,858,000
Pretax Income TTM
$-60,812,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-55,235,000
Free Cash Flow
$-31,708,250
Enterprise Value
$-23,734,082
Total Cash
$50,253,000
Total Debt
$10,919,000
Shares Out
2,500,000
Trailing EPS
$-21.64
Book Value
$13.76
ROE
-93.7%
ROA
-42.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 190,000 | -77,627,000 | -74,118,000 | 93,003,000 | 25,715,000 | 67,480,000 | -61,986,000 |
| Dec 2024 | 235,000 | -67,914,000 | -64,023,000 | 96,830,000 | 26,998,000 | 70,019,000 | -69,119,000 |
| Dec 2023 | 353,000 | -54,919,000 | -50,389,000 | 120,653,000 | 30,183,000 | 90,658,000 | -33,221,000 |
| Dec 2022 | 10,386,000 | -46,404,000 | -45,338,000 | 95,786,000 | 24,502,000 | 71,464,000 | -41,886,000 |
TTM Snapshot
Revenues TTM
$190,000
NetIncome TTM
$-60,807,000
OpCashFlow TTM
—
Assets (Latest)
$69,825,000
Forward EPS
$-18.74
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $4.08 · call oi: 9,333 · put oi: 197Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DYAI | DYADIC INTERNATIONAL INC | $12.66M | $0.32 | — |
| BCDA | BioCardia, Inc. | $11.93M | $0.79 | — |
| PASG | Passage BIO, Inc. | $13.58M | $4.22 | — |
| PLUR | Pluri Inc. | $14.09M | $0.98 | — |
| GRML | Greenland Mines Ltd | $10.87M | $3.42 | — |
News headlines (Yahoo Finance, 1h cache)
aTyr Pharma (ATYR) Stock Fair Value Moves Lower As Phase III Funding Risks Loom
2026-11-14 02:09 · Yahoo
aTyr Pharma to Participate in Upcoming Investor Conferences
2026-11-11 13:00 · Yahoo
Atyr Pharma: Q3 Earnings Snapshot
2026-11-05 21:26 · Yahoo
aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update
2026-11-05 21:01 · Yahoo
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
2026-10-29 12:00 · Yahoo
aTyr Pharma Announces One-for-40 Reverse Stock Split
2026-10-27 13:00 · Yahoo
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
2026-10-19 11:00 · Yahoo
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
2026-10-13 12:00 · Yahoo
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis
2026-09-24 14:59 · Yahoo
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
2026-09-24 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.